ADA 2026

Hypercortisolism is common and treatable in difficult-to-treat diabetes, analyses show

Presenters: Lance Sloan, MD, Texas Institute for Kidney and Endocrine Disorders, Lufkin, TX

Effects of mifepristone in people with difficult-to-control T2D and hypercortisolism on GLP-1RAs. Presented June 6, 2026.

Guillermo Umpierrez, MD, Emory University School of Medicine, Atlanta, GA

High prevalence of endogenous hypercortisolism in patients with type 2 diabetes and resistant hypertension: results from the MOMENTUM study. Presented June 7, 2026.

Machine-learning model identifies adults at highest risk for type 2 diabetes up to 10 years in advance, study data show

Presenter: Luis A. Rodriguez, PhD, MPH, RD, Kaiser Permanente Division of Research, Northern California

Machine-learning modeling for T2DM prediction in over 3 million adults. Abstract 2321-P. Presented June 6, 2026.

Berobenatide weight loss benefit maintained in shift to monthly dosing, phase 2b data show

Presenters: John B. Buse, MD, PhD, University of North Carolina School of Medicine, Chapel Hill, NC

The VESPER-1 OLE, -2 and -3 trials of berobenatide (MET-097, PF-08653944), an ultra-long-acting GLP-1 receptor agonist for weight management. Presented June 6, 2026.

Oral orforglipron lowered HbA1c and body weight across phase 3 comparisons in type 2 diabetes, ACHIEVE trials show

Presenter: Francesco Giorgino, MD, PhD, University of Bari Aldo Moro, Bari, Italy

From Pen to Pill: The Orforglipron ACHIEVE Clinical Trial Program. June 8, 2026.

Evolocumab reduced major cardiovascular events in patients with high-risk diabetes, VESALIUS-CV analysis shows

Presenter: Lawrence A. Leiter, MD, FRCPC, University of Toronto, Toronto, Canada

Evolocumab reduces CV events in patients with high-risk diabetes: Results from VESALIUS-CV. Presented June 7, 2026.

Survodutide substantially reduces weight and liver fat in adults with obesity, phase 3 SYNCHRONIZE studies show

Presenters: Carel le Roux, MD, PhD, University College Dublin School of Medicine, Dublin, Ireland
Lee M. Kaplan, MD, PhD, The Obesity and Metabolism Institute, Boston, MA, and Geisel School of Medicine at Dartmouth, Hanover, NH

The Benefits of Glucagon/GLP-1 Receptor Dual Agonism: Insights from the SYNCHRONIZE Phase 3 Studies of Survodutide. Presented June 7, 2026.

Continuous glucose monitoring in type 2 diabetes benefits people not on insulin, CONNECT trial shows

Presenter: Thomas W. Martens, MD, International Diabetes Center, Minneapolis, MN

CGM for Adults with Type 2 Diabetes Not on Insulin Therapy: The CONNECT Randomized Controlled Trial. Presented June 6, 2026.

Olezarsen lowers triglycerides and acute pancreatitis risk in severe hypertriglyceridemia with diabetes, phase 3 trial analyses show

Presenter: Yu Mi Kang, MD, PhD, MPH, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA

ApoC3 Inhibitor Olezarsen Markedly Reduces Triglycerides and Risk of Pancreatitis in Severe Hypertriglyceridemia Patients with Diabetes Mellitus: Insights from CORE-TIMI 72a and CORE2-TIMI 72b. Presented June 6, 2026.

Retatrutide yields substantial improvements in type 2 diabetes and obesity, phase 3 data from TRANSCEND-T2D-1 and TRIUMPH-1 show

Presenters: Harpreet S. Bajaj, MD, MPH, LMC Diabetes and Endocrinology, Brampton, ON, Canada (TRANSCEND-T2D-1)

Results of First Phase 3 Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist in Patients with T2D (TRANSCEND-T2D-1) and in Patients with Obesity (TRIUMPH-1). Presented June 6, 2026.

Ania M. Jastreboff, MD, PhD, Yale University, New Haven, CT (TRIUMPH-1)

Results of First Phase 3 Study of Retatrutide, a GIP, GLP-1, and Glucagon Receptor Agonist in Patients with Obesity (TRIUMPH-1). Presented June 6, 2026.